Family history of prostate cancer and the incidence of ERG‐ and phosphatase and tensin homolog‐defined prostate cancer

Family history is among the strongest known risk factors for prostate cancer (PCa). Emerging data suggest molecular subtypes of PCa, including two somatic genetic aberrations: fusions of androgen‐regulated promoters with ERG and, separately, phosphatase and tensin homolog (PTEN) loss. We examined associations between family history and incidence of these subtypes in 44,126 men from the prospective Health Professionals Follow‐up Study. ERG and PTEN status were assessed by immunohistochemistry. Multivariable competing risks models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between self‐reported family history of PCa and molecular subtypes of disease. Thirteen percent of men had a positive family history of PCa at baseline. During a median follow‐up of 18.5 years, 5,511 PCa cases were diagnosed. Among them, 888 were assayed for ERG status (47% ERG‐positive) and 715 were assayed for PTEN loss (14% PTEN null). Family history was more strongly associated with risk of ERG‐negative (HR: 2.15; 95% CI: 1.71–2.70) than ERG‐positive (HR: 1.49; 95% CI: 1.13–1.95) disease (pheterogeneity: 0.04). The strongest difference was among men with an affected father (HRERG‐negative: 2.09; 95% CI: 1.64–2.66; HRERG‐positive: 1.30; 95% CI: 0.96–1.76; pheterogeneity: 0.01). Family history of PCa was positively associated with both PTEN null (HR: 2.10; 95% CI: 1.26–3.49) and PTEN intact (HR: 1.72; 95% CI: 1.39–2.13) PCa (pheterogeneity: 0.47). Our results indicate that PCa family history may be positively associated with PCa in all ERG and PTEN subtypes, suggesting a role of genetic susceptibility in their development. It is possible that ERG‐negative disease could be especially associated with positive family history.

[1]  E. Rimm,et al.  A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. , 2019, European Urology.

[2]  Lauren E. Barber,et al.  Family History of Breast or Prostate Cancer and Prostate Cancer Risk , 2018, Clinical Cancer Research.

[3]  R. Hoover,et al.  TMPRSS2: ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences , 2017, American journal of epidemiology.

[4]  M. Loda,et al.  Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[5]  G. Sauter,et al.  PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort , 2017, Oncotarget.

[6]  B. Trock,et al.  Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. , 2017, European urology.

[7]  I. Mills,et al.  Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status , 2017, The Prostate.

[8]  M. Rubin,et al.  Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status , 2016, Human molecular genetics.

[9]  Kirsten L. Greene,et al.  Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer , 2016, Oncotarget.

[10]  Wennuan Liu.  DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer , 2016, Asian journal of andrology.

[11]  M. Loda,et al.  Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[12]  J. Stanford,et al.  Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status , 2015, Prostate Cancer and Prostatic Disease.

[13]  Stacey A. Kenfield,et al.  Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. , 2016, The American journal of clinical nutrition.

[14]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[15]  Jennifer R. Rider,et al.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. , 2015, Journal of the National Cancer Institute.

[16]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[17]  Pui-Yan Kwok,et al.  A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. , 2015, Cancer discovery.

[18]  J. Stanford,et al.  Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status. , 2015, American journal of epidemiology.

[19]  S. Srivastava,et al.  Predominance of ERG-negative high-grade prostate cancers in African American men. , 2014, Molecular and clinical oncology.

[20]  M. Loda,et al.  Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG–Positive Prostate Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[21]  K. Czene,et al.  The Heritability of Prostate Cancer in the Nordic Twin Study of Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[22]  J. Cuzick,et al.  Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer , 2013, British Journal of Cancer.

[23]  J. Hicks,et al.  Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion , 2013, Prostate Cancer and Prostatic Diseases.

[24]  S. Chambers,et al.  The influence of family history on cognitive heuristics, risk perceptions, and prostate cancer screening behavior. , 2013, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[25]  Jennifer R. Rider,et al.  The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[26]  J. Squire,et al.  Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration‐resistant prostate cancer , 2012, Histopathology.

[27]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[28]  G. Singh,et al.  Post-translational modifications of PTEN and their potential therapeutic implications. , 2011, Current cancer drug targets.

[29]  M. Rubin,et al.  TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients , 2011, The Prostate.

[30]  L. Holmberg,et al.  Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. , 2010, Journal of the National Cancer Institute.

[31]  M. Loda,et al.  Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation , 2010, Science Signaling.

[32]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[33]  R. Shah,et al.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.

[34]  M. Rubin,et al.  Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. , 2009, Cancer research.

[35]  O. Ludkovski,et al.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.

[36]  E. Giovannucci,et al.  Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era , 2008, The Prostate.

[37]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[38]  J. Trachtenberg,et al.  Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.

[39]  Yan Liu,et al.  Risk factors for prostate cancer incidence and progression in the health professionals follow‐up study , 2007, International journal of cancer.

[40]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[41]  R. Glynn,et al.  Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. , 2005, American journal of epidemiology.

[42]  Daniel J Schaid,et al.  The complex genetic epidemiology of prostate cancer. , 2004, Human molecular genetics.

[43]  R. Parsons.  Human cancer, PTEN and the PI-3 kinase pathway. , 2004, Seminars in cell & developmental biology.

[44]  Melissa M. Honour,et al.  Relation of family history of prostate cancer to perceived vulnerability and screening behavior , 2004, Psycho-oncology.

[45]  Laurence R. Paquette,et al.  Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. , 2002, Urology.

[46]  L. Clegg,et al.  Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. , 2002, Archives of internal medicine.

[47]  C Coley,et al.  Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. , 2001, Urology.

[48]  C. Eng,et al.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. , 2000, The American journal of pathology.

[49]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.